Navigation Links
Penn study shows 2-sided immune cell could be harnessed to shrink tumors
Date:10/28/2010

PHILADELPHIA - A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.

This new understanding that Th17 cells manage to play both sides of the fence suggests that targeting or inhibiting the involved protein pathways might be a new way to treat cancer, chronic infection, and some autoimmune diseases. Previous studies have linked excessive amounts of Th17 cells in the body to such autoimmune diseases as multiple sclerosis, psoriasis, rheumatoid arthritis, and Crohn's disease.

First author and postdoctoral fellow Chrystal Paulos PhD; senior author Carl June, MD, professor of Pathology and Laboratory Medicine, and colleagues have found that a protein called inducible costimulator (ICOS) is necessary for the growth and function of human Th17 cells, while CD28, a transmembrane protein on CD4 cells, stops the ICOS signal. What's more, human Th17 stimulated with ICOS shrank human tumors implanted in a mouse model faster than those stimulated with CD28. The findings appear in this week's Science Translational Medicine. June is also the Program Director of Translational Research for the Abramson Family Cancer Research Institute at Penn.

These findings were surprising to the researchers given that CD28 has historically been used by investigators to study and expand human Th17 cells. The new data on Th17 cells raises the possibility that the full inflammatory potential of human Th17 cells had not been fully reflected by previous lab studies.

To move this knowledge closer to the clinic, the team also demonstrated that Th17 cells cannot only be expanded to large numbers, but could also be maintained by stimulating them with ICOS proteins. Th17 polarizing cytokines have previously been shown to support Th17 cells from nave CD4 cells but this is the first demonstration that the ICOS costimulatory molecule used to expand the Th17 cells is important.

Tilting the balance between spurring and suppressing the growth of Th17 cells may be a key to tailoring immunotherapy, a form of cancer treatment. Adoptive transfer of tumor-specific cells expanded with ICOS and polarized to a Th17 cell type might further improve treatment.

These basic findings on Th17 cells in both peripheral and cord blood cells has broad implications, providing the basis of a new human cancer treatment protocol. T-cell-based therapies that incorporate the ICOS signal are being planned at Penn to treat patients with leukemia.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert  

Related biology news :

1. Texas A&M University becomes key player in global study to save Earths endangered species
2. Study suggests a third of shark and ray species are threatened
3. Study identifies key molecules in multiple myeloma
4. Landenberger Foundation awards grant to Scripps Florida scientist to study HIV
5. Penn study identifies molecular guardian of cells RNA
6. LSUHSC study IDs proteins regulating water retention in salt-sensitive hypertension
7. Offshore wind a mixed bag: University of Maryland study
8. Modeling study identifies characteristics of high elk-use areas in western Oregon, Washington
9. Universities receive grants to study climate change decisions
10. Center to study effects of plastics chemicals on childrens health
11. Study of tiny magnets may advance their use in microelectronics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penn study shows 2-sided immune cell could be harnessed to shrink tumors
(Date:11/17/2016)... Global Market Watch: Primarily supported by ... Banks and Academics) market is to witness a value of ... the highest Compounded Annual Growth Rate (CAGR) of 10.75% is ... analysis period 2014-2020. North America is ... Europe at 9.56% respectively. Report ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... 5, 2016  Eisai Inc. announced today final ... of rufinamide, which were presented at the 2016 ... held from December 2-6 in Houston, ... tolerability and cognitive data showed that patients who ... and tolerability profiles, cognitive development and behavior, compared ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016  In ... Society of Hematology (ASH) Annual Meeting and Exposition in ... advanced biomedical engineering methods to improve the delivery of ... conditions. These new methods are designed to carry therapies ... are needed most, which could provide a substantial advantage ...
(Date:12/2/2016)... Calif. , Dec. 2, 2016 Amgen (NASDAQ: ... AGN ) today announced the submission of a Marketing Authorization ... 215, a biosimilar candidate to Avastin ® (bevacizumab). The ... submitted to the EMA. "The submission of ... Amgen seeks to expand our oncology portfolio," said Sean ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... pneumatic tube systems for North American hospitals, will present its chain-of-custody solution for ... and Exhibition in Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a ...
Breaking Biology Technology: